Genitourinary Cancers

The FDA has granted an accelerated approval to atezolizumab as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on the future of treatments for patients with renal cell carcinoma (RCC).

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses savolitinib in papillary renal cell cancer.

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on combinations of targeted therapies for patients with renal cell carcinoma (RCC).

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Axitinib was a promising newcomer in the renal cell carcinoma field when it was introduced as a second-line therapy 5 years ago. Now it is being displaced by newer therapies, a development that may serve as a harbinger for the evolution of treatment patterns in other tumor types with a bounty of novel agents.

David M. Nanus, MD, discusses evolving therapeutic strategies in the neoadjuvant and adjuvant setting for patients with renal cell carcinoma.

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses the treatment of hereditary leiomyomatosis and renal cell cancer (HLRCC).

David I. Quinn, PhD, MBBS, discusses the latest advances with targeted agents in renal cell caricinoma, including combination regimens with checkpoint inhibitors.

Evan Y. Yu, MD, discusses the current treatment options for patients with metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

Scott Tagawa, MD, discusses the latest findings with sacituzumab govitecan in patients with metastatic urothelial cancer.

As the number of tumor types with approved PD-1/PD-L1 pathway inhibitors continues to expand, bladder cancer has become a robust area of development.